Navigation Links
Halozyme Therapeutics to Host Analyst Meeting on October 14 in New York
Date:10/7/2010

SAN DIEGO, Oct. 7 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that it will host a meeting for analysts and investors on October 14, 2010 in New York. During the meeting, Halozyme's management will present a review of its proprietary product development pipeline, business alliances with Roche and Baxter, and an update on other aspects of its business strategy.  

(Logo:  http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100302/LA63139LOGO)

Presenters at the meeting will include Jonathan Lim, M.D., president and CEO, Gregory I. Frost, Ph.D., chief scientific officer, Kurt Gustafson, chief financial officer, Robert Little, chief commercial officer, and Doug Muchmore, M.D., vice president, endocrinology clinical development.  

Halozyme will conduct a live webcast of the presentations beginning at approximately 12:15 p.m. EDT. To access the webcast over the Internet, please go to the company Web site at www.halozyme.com. An archive of the presentation will be available on Halozyme's Web site shortly after the conclusion of the meeting.

About HalozymeHalozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enh
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Halozyme Therapeutics Announces Public Offering of Common Stock
2. Halozyme Provides HYLENEX® Product Reintroduction Update
3. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
4. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
5. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
6. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
7. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
8. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
9. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
10. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
11. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... PROSPECT, Ill. , June 18, 2013 /PRNewswire-iReach/ ... of its new X3130 Appliance Inlet Module. The ... circuit breaker , combines a C14 appliance inlet ... one compact package.  This three-in-one device allows design ... their designs - cutting installation time by 66 ...
(Date:6/18/2013)... Mass. , June 18, 2013 ... the company was named Overall Performance Leader in Imaging ... Equipment & Infrastructure report. Philips also received Best in ... its imaging products: Ingenuity Core 128 Computed Tomography ... ultrasound and PageWriter TC70 cardiograph. The annual Best in ...
(Date:6/18/2013)... 18, 2013 Unilife Corporation ("Unilife" or "Company") ... and manufacturer of injectable drug delivery systems, today announced ... www.unilife.com . The new site includes additional products, videos, ... on a regular basis. Mr. Alan ... emerging global leader for injectable drug delivery systems, we ...
Breaking Medicine Technology:Three-in-One X3130 Appliance Inlet Module 2Philips Named 2013 Overall Performance Leader In Imaging Equipment By KLAS 2Unilife Launches New Corporate Website 2
... Inc. (Nasdaq: MSHL ), an oncology company ... cancer metabolism, announced today that it has filed a ... Exchange Commission for a rights offering to existing stockholders ... stock. The Company will announce further details regarding the ...
... Feb. 21, 2012  Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ... will present a company overview at Citi,s 2012 Global Health ... ET at the Waldorf Astoria in New York City. ... available on the "Investors & Media" section of the Company,s ...
Cached Medicine Technology:Marshall Edwards Announces Rights Offering to Stockholders 2Marshall Edwards Announces Rights Offering to Stockholders 3
(Date:6/19/2013)... June 19, 2013 Imprivata ®, ... today announced that Imprivata OneSign ® leads the ... Mid-Term Performance Review: Software & Services report . CIOs ... Imprivata on the superior performance of its products and ... they indicate that Imprivata is integral to their long-term ...
(Date:6/19/2013)... Kona, HI (PRWEB) June 19, 2013 ... coordination company is dedicated to being an effective and ... wedding, reception needs. They have partnered up with Tom ... advice and discounts on most of Hawaii’s activities. , ... shows how clients can get the lowest prices on ...
(Date:6/19/2013)... The producers of Viewpoints TV are pleased ... city is located in the center of what is called ... image and become an affordable city to live, work, raise ... the United States with a workforce strong in the high ... cost-of-living, friendly business environment and more than 100 days of ...
(Date:6/19/2013)... School of Nursing researcher has received a four-year, $1.49 ... mood in women with diabetes who are depressed. , ... can reduce blood pressure and affect how well women ... Institute of Nursing Research at the National Institutes of ... and colleagues hypothesize that women receiving vitamin D will ...
(Date:6/19/2013)... Chicago is cracking down on bed bugs. New ... will require landlords to exterminate any and all reported bed ... ordinance also makes tenants responsible for reporting signs of bed ... often include disposing of furniture, bedding, and more. , In ... did more bed bug business in Chicago than any other ...
Breaking Medicine News(10 mins):Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 3Health News:Maui'd Forever Pleased to Offer Price Guarantee on Hawaii Activities 2Health News:Viewpoints TV Announces June Air Dates for Phoenix, AZ 2Health News:Loyola receives $1.5 million grant to study vitamin D for diabetes and depression 2Health News:Chicago Ordinance Requires Landlords and Tenants to Take Responsibility for Bed Bugs 2
... enough to guarantee complete parity in treatment, expert says ... guidelines from the American Heart Association have been able ... heart attack patients, a new study finds. , Called ... in care can be eliminated while at the same ...
... may sound simple, but not so in the formation of ... implications, Mitchell A. Lazar, M.D., Ph.D., director of the Institute ... School of Medicine, and colleagues report in the current issue ... intermediate state between early-stage fat cells and fully mature ones ...
... ... ... 17, 2010 -- Centegra Health System and Dell Services ( www.dell.com ) ... region’s first-ever Health Information Exchange (HIE). The program also provides local physicians with access ...
... that may prove to be a more effective treatment for ... Press in the May issue of the journal Cancer ... notoriously intractable leukemia stem cells that often escape standard treatment ... myelogenous leukemia (CML) is a deadly form of leukemia that ...
... available in French . , Montreal, May ... links between cell phone use and brain tumours is ... the Interphone International Study Group. Jack Siemiatycki, a professor ... the University of Montreal Hospital Research Center, says restricted ...
... for tests that predict the illness, researchers say , MONDAY, ... disease in middle age may have genetic roots, even if ... illnesses in their background, a new study has found. , ... to screen for genetic predispositions to serious lung disease before ...
Cached Medicine News:Health News:Heart Attack Guidelines Close Racial Gaps in Hospital Care 2Health News:Heart Attack Guidelines Close Racial Gaps in Hospital Care 3Health News:A fat cell grows up 2Health News:A fat cell grows up 3Health News:Centegra Health System Launches New Physician Network 2Health News:Centegra Health System Launches New Physician Network 3Health News:Combination therapy targets stubborn leukemia stem cells 2Health News:World's biggest study on cell phones and brain cancer inconclusive 2Health News:Lung Disease Can Be Genetic Even Without Family History 2
... Paradigm II utilizes powerful ... modules that provide complete flexibility for you to ... Quality system, while providing transparent accountability to all ... or Intranet . Paradigm II uses ...
... is the power behind each MasterControl ... the essential building blocks to construct ... to boost operational efficiency, improve product ... and quality standards. Click here to ...
... automated, easy to operate and maintain. The ... by flexible snap-seal pockets which minimize the ... of the water. Offered in two-, four-, ... accommodate bags of various sizes. ThermoLine Thawing ...
... Our thawing systems are automated, easy to ... from the outside environment by flexible snap-seal ... bacterial or viral contamination of the water. ... the systems can also accommodate bags of ...
Medicine Products: